Zhou Hengbo, Lei Pin-Ji, Padera Timothy P
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) Cancer Center, MGH and Harvard Medical School (HMS), Boston, MA 02114, USA.
Cells. 2021 Mar 12;10(3):627. doi: 10.3390/cells10030627.
Lymph nodes are the most common sites of metastasis in cancer patients. Nodal disease status provides great prognostic power, but how lymph node metastases should be treated is under debate. Thus, it is important to understand the mechanisms by which lymph node metastases progress and how they can be targeted to provide therapeutic benefits. In this review, we focus on delineating the process of cancer cell migration to and through lymphatic vessels, survival in draining lymph nodes and further spread to other distant organs. In addition, emerging molecular targets and potential strategies to inhibit lymph node metastasis are discussed.
淋巴结是癌症患者最常见的转移部位。淋巴结疾病状态具有很强的预后指示作用，但对于如何治疗淋巴结转移仍存在争议。因此，了解淋巴结转移进展的机制以及如何针对这些机制进行治疗以获得治疗益处非常重要。在本综述中，我们重点阐述癌细胞迁移至淋巴管并穿过淋巴管、在引流淋巴结中存活以及进一步扩散至其他远处器官的过程。此外，还讨论了新兴的分子靶点和抑制淋巴结转移的潜在策略。
